Current Approach to Secondary Lymphoedema on Gynaecological Cancer

ESGO eAcademy, Jaume Masia Ayala, 411033

Durvalumab Plus Carboplatin/Paclitaxel Followed By Durvalumab ± Olaparib As A First-Line Treatment For Newly Diagnosed Advanced Or Recurrent Endometrial Cancer: Results From The Phase III DUO-E/GOG-3041/ENGOT-EN10 Trial

ESGO eAcademy, Marta Gil-Martin, 411023

Pathology and Molecular Features of Clear Cell Ovarian Carcinoma

ESGO eAcademy, Glenn McCluggage, 411029

Taking the Reconstruction Elevator for Gynaecological Reconstruction

ESGO eAcademy, Jung-Ju Huang, 411032

Case Presentation: Case of 45-Year-Old with Newly Diagnosed Stage 3 Ovarian Clear Cell Carcinoma

ESGO eAcademy, Kosei Hasegawa, 411028

Phase III Double-Blind Randomized Placebo Controlled Trial Of Atezolizumab In Combination With Carboplatin And Paclitaxel In Women With Advanced/Recurrent Endometrial Carcinoma: The Asian Cohort Of AtTEnd/ENGOT-EN7 Trial

ESGO eAcademy, Shin Nishio, 411022

Presidential Talk

ESGO eAcademy, Nicole Concin, 411021

Introduction of the ESGO president

ESGO eAcademy, Ignace Vergote, 411020

Understanding Endometrial Cancer from the Pathology Perspective

ESGO eAcademy, Xavier Matias-Guiu, 411019

Introduction and Announcement of the ESGO Helga Salvesen Translational and Clinical Research Award

ESGO eAcademy, Mansoor Raza Mirza, 411018

Advantages and Limitations of OSNA and Ultrastaging - The Pathologist’s Point of View

ESGO eAcademy, Xavier Matias-Guiu, 411017

OSNA for the Detection of SLN Metastases in Cervical Cancer - An Overview of the Performance and Survival Data

ESGO eAcademy, Francesco Fanfani, 411016

Effectivity of OSNA Method in Endometrial Cancer: A Large Retrospective Multicenter Study

ESGO eAcademy, Ignacio Zapardiel, 411015

Opening Remarks

ESGO eAcademy, Giovanni Scambia, 411013

Molecular Subgroups Versus Risk Of Sentinel Lymph Node Metastases And Recurrence In Endometrial Cancer

ESGO eAcademy, Lombaers Marike, 411003

Risk-Reducing Prophylactic Fimbriectomy Followed By Delayed Ooforectomy In Women At Risk Of Ovarian Cancer: Results Of A Single-Center Retrospective Analysis

ESGO eAcademy, Mathilde Duchatelet, 411002

Time Matters, Quality Makes The Most: The Experience Of An Italian Referral Center Including PALND In Treatment Algorithm For LACC

ESGO eAcademy, Elena Olearo, 411001

10 Years Of Double-Barrel Wet Colostomy: A Single-Institution’s Experience Performing An Alternative Diversion In Patients Undergoing Total Pelvic Exenteration For Gynecologic Malignancy

ESGO eAcademy, Maureen Byrne, 411000

Looking Beyond Immunotherapy in Endometrial Cancer: The Role of ADCs

ESGO eAcademy, Domenica Lorusso, 411006

Seneca Sentinel: Risk Factors For Unsuccessful Bilateral Sentinel Lymph Node Mapping In Endometrial Cancer

ESGO eAcademy, Felix Boria, 410998

Benefit From Atezolizumab In Patients With A Poor Prognostic Ovarian Cancer In First-Line Setting: IMAGYN-050 Trial

ESGO eAcademy, Benoit You, 410997

Cost-Effectiveness Analysis Of Cancer Susceptibility Gene-Specific Prevention Strategies For Ovarian And Breast Cancer

ESGO eAcademy, Xia Wei, 410996

Risk Factors For The Recurrence In Patients With Early Endometrioid Endometrial Cancer Achieving Complete Remission For Fertility-Sparing Hormonal Treatment

ESGO eAcademy, Jang Eun Bi, 411790

Beating Metastatic/Recurrent Cervical Cancer through a Novel Therapeutic Approach, the ADCs

ESGO eAcademy, Ana Oaknin, 411005

Risk Factors For The Recurrence In Patients With Early Endometrioid Endometrial Cancer Achieving Complete Remission For Fertility-Sparing Hormonal Treatment

ESGO eAcademy, Jang Eun Bi, 410995

The Application Value Of CDO1 And CELF4 Dual-Gene Methylation Testing In Screening For Endometrial Cancer In Women With Abnormal Uterine Bleeding

ESGO eAcademy, Bingxin Cai, 410994

Safety And Efficacy Of Durvalumab (D) + Tremelimumab (T) + Metronomic Oral Vinorelbine (MOV) In Patients With Recurrent/Metastatic Cervical Cancer (RMCC) In The MOVIE Trial.

ESGO eAcademy, Jean-Sebastien Frenel, 410993

Expanding the Advanced Ovarian Cancer Treatment Landscape in the Relapse Setting

ESGO eAcademy, Jean Emmanuel Kurtz, 411004

Compliance With Follow-Up After Low-Grade Cervical Smear Results And The Long Term Risk Of Developing Cervical Cancer.

ESGO eAcademy, Ruud Bekker Bekkers, 410992

Surgical Approach, Preoperative LEEP/Cone Biopsy And Patterns Of Recurrence And Death In Low-Risk Cervical Cancer - Analysis Of The International CCTG CX.5/SHAPE Phase III Trial

ESGO eAcademy, Marie Plante, 410988

Tumour Size Assessment In Patients With Early-Stage Cervical Cancer And Its Impact On A Tailored Management: Final Results Of A Prospective, International Multicenter Study SENTIX (CEEGOG CX-01; ENGOT-CX2)

ESGO eAcademy, Kocian Roman, 410987

Quality Assurance For Surgery And Pathology For Patients Randomized Before 2022 In SENTICOL III (International Validation Study Of Sentinel Node Biopsy In Early Cervical Cancer).

ESGO eAcademy, Fabrice Lecuru, 410986

Risk Factors For Lymph Node Metastasis In Women With Cervical Cancer Who Have Small Volume Disease

ESGO eAcademy, Hans Wenzel, 410985

Ultrasound in the Hands of Gynaecologists/Gynaecological Oncologists as an Effective Alternative to CT, WB-DWI/MRI or PET-CT?

ESGO eAcademy, Daniela Fischerova, 410991

Evaluating The Safety Of Less Radical Surgery In Node Negative Stage IA1-IB1 Cervical Cancer With Positive Lymphovascular Space Invasion

ESGO eAcademy, Christian Dagher, 410984

Evaluation Of The Effectiveness And Safety Of Disitamab Vedotin For HER2-Expressing Recurrent Cervical Cancer After Progression On Platinum-Based Treatment-A Single-Arm, Multicenter, Open-Label, Phase II Clinical Study

ESGO eAcademy, Jinwei Miao, 410983

Efficacy And Safety Of Iparomlimab And Tuvonralimab In Previously Treated Patients With Recurrent Or Metastatic Cervical Cancer: A Multicenter, Open-Label, Single-Arm, Phase 2 Clinical Trial (DUBHE-C-206)

ESGO eAcademy, Jihong Liu, 410982

Standard Imaging Modality (CECT, Whole-Body DWI-MRI or FDG-PET-CT (a Radiologist's View)

ESGO eAcademy, Ingfrid Haldorsen, 410990

Comparing Adjuvant External Beam Radiotherapy With Brachytherapy To External Beam Radiotherapy Alone In Intermediate-Risk Cervical Cancer

ESGO eAcademy, Nuria Garcia, 410981

Summary and Discussion

ESGO eAcademy, Beyhan Ataseven, 410974

Low Anterior Resection Syndrome

ESGO eAcademy, Beyhan Ataseven, 410973

Lower Leg Lymphoedema

ESGO eAcademy, Artem Stepanyan, 410972

A Young Patient with Metastatic Choriocarcinoma

ESGO eAcademy, Christianne Lok, 410979

Vaginal Discomfort and Sexual Disfunction

ESGO eAcademy, Alexandra Strojna, 410971

Open Debulking Surgery for Advanced Ovarian Cancer

ESGO eAcademy, Christina Fotopoulou, 410975

Welcome

ESGO eAcademy, Alexandra Strojna, 410970

Prevention And Treatment Of Incisional Hernia After Laparotomy In Gynecologic Oncology. Abdominal Wall Closure With Mesh.

ESGO eAcademy, Ana Conde Adán, 410963

CYTOREDUCTION OF PARA-AORTIC LYMPH NODES PERFORMED BY ROBOTIC-ASSISTED SURGERY

ESGO eAcademy, Samuel Pérez, 410962

How to Approach „Out of the Box“ Cases

ESGO eAcademy, Frederic Amant, 410969

Liquid Biopsy Assessment to Improve Risk-Prediction, Follow-Up and Therapy Selection of Endometrial Cancer: Moving Towards a Clinical Application

ESGO eAcademy, Laura Muinelo, 410966

3D-Printing The Cancer: A New Frontier Of Surgical Planning For Complex Pelvic Resections

ESGO eAcademy, Maureen Byrne, 410961

Is There Any Chance in Uterine Sarcomas?

ESGO eAcademy, Ignacio Zapardiel, 410968

Tips And Techniques To Optimize Access To Difficult Areas In Cytoreductive Surgery Of The Upper Abdomen

ESGO eAcademy, Lana Bijelic, 410960

How Might We Maximise the Utility of Liquid Biopsy in Ovarian Cancer Management?

ESGO eAcademy, Gourley Charlie, 410965

How To Reduce Anterior Resection Syndrome And Post-Operative Complication After Recto-Sigmoid Resection

ESGO eAcademy, Giulio Ricotta, 410959

Navigating Fertility Sparing Counseling

ESGO eAcademy, Ilker Kahramanoglu, 410967

Clinical Applications of ctDNA Testing in Gynaecological Tumours

ESGO eAcademy, Nicola Normanno, 410964

Transdiaphragmatic Cardiophrenic Lymph Node Resection

ESGO eAcademy, Jalid Sehouli, 411446

Progression-Free Survival 2-Progression-Free Survival 1 In Patients With Primary Advanced/Recurrent Endometrial Cancer Treated With Dostarlimab Plus Chemotherapy Compared With Chemotherapy Alone In The ENGOT-EN6-NSGO/GOG-3031/RUBY Trial

ESGO eAcademy, Carolyn McCourt, 410952

When Design Fails

ESGO eAcademy, Robert L Coleman, 410958

Sexual Health And Quality Of Life After Molecular-Based Adjuvant Treatment In The Randomised PORTEC-4a Trial

ESGO eAcademy, Anne-Sophie van den Heerik, 410951

Consolidation Courses In Low-Risk Gestational Trophoblastic Neoplasia And Relapse Rate: A MITO-9 Study

ESGO eAcademy, Raffaella Cioffi, 410950

Update on New Developments in Maintenance

ESGO eAcademy, Kathleen Moore, 410955

Pregnancy Complications And Outcomes In Early Endometrial Cancer And Atypical Hyperplasia Patients After Fertility Preserving Treatment

ESGO eAcademy, Xiaojun Chen, 410949

Randomisation is Not a Holy Grail

ESGO eAcademy, David Cibula, 410957

COPELIA: A 3-Arm Randomised Phase II Trial Of Weekly Paclitaxel With Or Without Cediranib Or Olaparib With Cediranib In Recurrent Endometrial Cancer.

ESGO eAcademy, Andrew Clamp, 410948

Challenges in the PARPi Era: From Oligo-Progression to Impact of PARPi in Subsequent Lines

ESGO eAcademy, Kristina Lindemann, 410954

TROPHIMMUN, Cohort A: Maintained Benefit From Second-Line Avelumab After Failure To Monochemotherapy In Low-Risk Gestational Trophoblastic Tumor, With A 4 Year-Follow-Up.

ESGO eAcademy, Pierre-Adrien Bolze, 410946

There is Only One Level A Evidence

ESGO eAcademy, Mansoor Raza Mirza, 410956

Patient Selection for Maintenance in Front Line: Dealing with the Controversies of Current Biomarkers (BRCA, HRD & Kelim)

ESGO eAcademy, Antonio Gonzalez Martin, 410953

Selinexor Maintenance For Patients With TP53wt Advanced Or Recurrent Endometrial Cancer: Long-Term Follow Up Of Efficacy And Safety Subgroup Analysis Of The ENGOT-EN5/GOG-3055/SIENDO Study

ESGO eAcademy, Jalid Sehouli, 410945

FIGO IV - When Is the Best Time to Opt for Neoadjuvant Treatment

ESGO eAcademy, Toon Van Gorp, 410941

Abnormal Colposcopy and Challenges of Colposcopy

ESGO eAcademy, Grigore Mihaela, 410944

Optimization of Fertility Results and Infertility Management

ESGO eAcademy, Michael Grynberg, 410937

HPV DNA, mRNA, and Self Tests

ESGO eAcademy, Murat Gultekin, 410943

Management of Cervical Cancer

ESGO eAcademy, Giovanni Scambia, 410936

FIGO IV - Management and Outcome in Clinical Reality

ESGO eAcademy, Kristina Lindemann, 410938

Brief History and Methodology of the Project and Management of Ovarian Tumours

ESGO eAcademy, Philippe Morice, 410935

HPV Vaccines: Up-to-Date Evidence

ESGO eAcademy, Elmar Joura, 410942

Motivation and Innovation

ESGO eAcademy, Hugo de Lacy, 410934

InnovaTV 301/ENGOT-Cx12/GOG-3057: A Global, Randomized, Open-Label, Phase 3 Study Of Tisotumab Vedotin Versus Investigator’s Choice Of Chemotherapy In 2L Or 3L Recurrent Or Metastatic Cervical Cancer

ESGO eAcademy, Antonio Gonzalez Martin, 410929

BEATcc (ENGOT-CX10/GEICO 68-C/JGOG1084/GOG-3030), A Randomised Phase 3 Trial Of First-Line Atezolizumab With Bevacizumab And Platinum-Based Chemotherapy For Metastatic (Stage IVB), Persistent Or Recurrent Cervical Cancer

ESGO eAcademy, Ana Oaknin, 410928

Patient-Reported Outcomes From The Phase 3, Randomized, Double-Blind, Placebo-Controlled ENGOT-Cx11/GOG 3047/KEYNOTE-A18 Study Of Pembrolizumab Plus Concurrent Chemoradiotherapy In Patients With High-Risk Locally Advanced Cervical Cancer

ESGO eAcademy, Sandro Pignata, 410926

A Randomized Phase III Trial Of Induction Chemotherapy Followed By Chemoradiation Compared With Chemoradiation Alone In Locally Advanced Cervical Cancer. The GCIG INTERLACE Trial

ESGO eAcademy, Mary McCormack, 410925

Discussant

ESGO eAcademy, Toon Van Gorp, 410930

Discussant

ESGO eAcademy, Remi Nout, 410927

Discussant

ESGO eAcademy, Nadeem R. Abu-Rustum, 410924

Survival Of Patients With Early Stages Cervical Cancer After SLN Biopsy Without Systematic Pelvic Lymphadenectomy: Survival Outcomes Of The SENTIX Prospective Single-Arm International Trial (CEEGOG CX-01; ENGOT-CX2)

ESGO eAcademy, David Cibula, 410923

Immuno and Immune-Combo: Toxicity Management

ESGO eAcademy, Kathleen Moore, 410922

Is there a Place for Immune after Immuno in Endometrial Cancer (alone or in combination)?

ESGO eAcademy, Robert L Coleman, 410921

Endometrial Cancer: A Paradigm Shift in the Treatment Algorithm

ESGO eAcademy, Christian Marth, 410920

The VITA MCQ Test

ESGO eAcademy, Faculty / Presenters, 410906

Ultrasound Guided Procedures (ESGO/ISUOG Consensus Statement)

ESGO eAcademy, Elisabeth Epstein, 410905

Vulvar Cancer Staging Using Ultrasound (ESGO Guidelines)

ESGO eAcademy, Daniela Fischerova, 410903

Ovarian Cancer Precision Prevention: improving ascertainment and personalised surgical approaches

ESGO eAcademy, Faculty / Presenter(s), 411368

Sentinel lymph node dissection

ESGO eAcademy, Faculty / Presenter(s), 411242

New EC FIGO staging system

ESGO eAcademy, Faculty / Presenter(s), 410593

Updates on surgical trials in gynecologic oncology

ESGO eAcademy, Faculty / Presenter(s), 410592

Systemic therapy for uterine LMS

ESGO eAcademy, Faculty / Presenter(s), 410591

Is there a role of predictive biomarkers for endocrine therapy in gynecological malignancies?

ESGO eAcademy, Faculty / Presenter(s), 410590